Is an rct of bpc-157 where 2/3 of 1000 participants get ampoules of lyophilized active drug and 1/3 get placebo a good idea?

Sonar Pro

Vote: No

A proposed RCT of BPC-157 with 1000 participants, 2/3 active and 1/3 placebo, violates core principles of randomized controlled trials. Standard RCTs use **1:1 randomization** (50/50) to ensure balanced groups, minimize bias, and maximize statistical power for detecting treatment effects[1][4]. This 2:1 ratio introduces imbalance, reducing power and risking type II errors, especially for an unproven drug like BPC-157. BPC-157 lacks robust human evidence: a Phase I trial (n=42) was completed but results unpublished[1][5][7]; other studies are small, uncontrolled, or from conflicted sources[2][3][5][7]. It's unapproved by regulators (FDA Category 2, WADA-prohibited)[4][5], with unknown long-term risks like cancer promotion[5]. Jumping to a large efficacy RCT skips necessary Phase II dosing/safety data. Lyophilized ampoules imply injection (vs. oral in prior trial[1]), untested in humans at scale, heightening safety concerns without pharmacokinetic justification[1][5]. Resources for 1000 participants are better allocated after smaller, balanced Phase II trials. This design is scientifically flawed and ethically risky.

GPT-5.4

Vote: No

A 1000-person RCT is only a good idea if there is strong preclinical rationale, robust manufacturing quality, a clear dose/formulation rationale, and enough human safety data to justify exposing hundreds of people. For BPC-157, those prerequisites are not well established. The proposed design also glosses over major specifics that determine whether a trial is ethical and useful: indication, route of administration, dosing schedule, endpoints, safety monitoring, and regulatory-grade product quality. "Ampoules of lyophilized active drug" is a formulation detail, not a clinical justification. A 2:1 randomization can be reasonable, but it makes sense mainly after there is enough confidence that the intervention is worth testing at scale. Without stronger prior evidence, this risks creating a large, expensive, and potentially unethical trial that is unlikely to produce actionable results. A better idea would be a smaller, tightly controlled phase 1/2 study first, focused on safety, pharmacology, product quality, and a specific indication. If those data are promising, then a larger RCT could be justified.

Grok 4.1 Fast

Vote: No

Standard RCT design prioritizes 1:1 randomization for maximal statistical power with a fixed sample size. Here, a 2:1 active-to-placebo ratio (667:333) reduces power to detect true effects, as efficiency is optimized at equal groups per the formula for variance in difference of means. No justification is given for imbalance, such as ethical concerns or cost savings, making it statistically suboptimal without gain. BPC-157 lacks robust human safety data (mostly animal/preliminary studies), so prioritizing more exposed participants over rigorous science risks ethical issues and unreliable results. Lyophilized ampoules require identical placebo for blinding, but imbalance undermines overall trial quality for an unapproved compound.

Gemini 3.1 Pro

Vote: No

A 1000-participant trial is effectively a Phase III clinical trial. Jumping to a study of this magnitude is a terrible idea because BPC-157 currently lacks the robust Phase I and Phase II human safety, tolerability, and dosing data required to justify exposing nearly 700 people to an experimental peptide. Furthermore, there are massive regulatory and safety red flags. The FDA recently prohibited the compounding of BPC-157 precisely because there is insufficient evidence regarding its safety profile in humans (and it is banned by WADA). Moving forward with a massive trial without this safety foundation violates Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. Finally, supplying lyophilized ampoules implies subcutaneous or intramuscular injection. This introduces additional risks, such as infection or severe localized immune reactions, which must first be tested in small, tightly monitored clinical settings rather than a massive 1000-person cohort.

Claude Opus 4.6

Vote: No

While an RCT of BPC-157 would be scientifically valuable in principle, this specific design has several serious problems. First, BPC-157 (Body Protection Compound-157) has never completed proper Phase I/II human safety trials. Jumping to a 1,000-participant trial without adequate dose-finding and safety data from smaller studies violates standard clinical development principles and puts participants at unnecessary risk. Second, BPC-157 is a peptide that currently lacks regulatory approval in any jurisdiction for therapeutic use. Conducting a trial of this size would require IND (Investigational New Drug) approval from the FDA or equivalent regulatory body, which would be extremely difficult to obtain without prior Phase I data establishing safety, pharmacokinetics, and dosing. Third, the 2:1 randomization (active:placebo) is not inherently problematic, but distributing lyophilized drug in ampoules to 667 participants implies a scale of manufacturing that would require GMP-grade production. The peptide supplement market is notoriously poorly regulated, and ensuring pharmaceutical-grade purity and consistency at this scale would be a major challenge. Fourth, the question doesn't specify an indication, primary endpoint, or patient population. A well-designed RCT needs a clear therapeutic hypothesis. BPC-157 has been studied in animal models for diverse conditions (gut ulcers, tendon healing, etc.), but without a specific, well-justified clinical indication, a 1,000-person trial is premature and wasteful. Finally, exposing 667 people to an inadequately characterized investigational peptide when the existing human evidence is essentially anecdotal raises serious ethical concerns. The proper approach would be small Phase I safety studies first, then dose-finding Phase II trials, before scaling to this size. The concept of rigorously studying BPC-157 is good, but this specific proposal skips essential steps in clinical development.

Kimi K2.5

Vote: No

This trial design is problematic primarily because BPC-157 is an unapproved experimental peptide with limited human safety data. Exposing approximately 667 participants to an active compound of uncertain toxicity profile in a large Phase II-style trial is ethically questionable and premature. Regulatory agencies typically require robust Phase I safety data before enrolling hundreds of participants. The 2:1 allocation ratio is statistically inefficient. For a fixed total sample size of 1000, a 667/333 split yields substantially less power to detect a given effect size compared to a balanced 500/500 design. If the goal is to gather safety data on the active drug, 1:1 allocation remains standard unless there is compelling evidence of large effect sizes and minimal risk—neither of which is established for BPC-157. Finally, conducting such a large trial with lyophilized ampoules (implying injection) increases risk exposure without clear justification. A smaller, balanced RCT with rigorous safety monitoring would better serve scientific and ethical standards before scaling to larger cohorts.

Final Summary

The AI Roundtable reached a swift and unanimous consensus, rejecting the proposed BPC-157 trial as a statistically inefficient ethical minefield. Led by Gemini 3.1 Pro and Claude Opus 4.6, the models argued that jumping to a 1,000-person study for an unapproved peptide without foundational Phase I safety data is a dangerous violation of clinical standards.

All 6 models agreed on "No" after discussion

Strongest Arguments

• No: The proposed trial is effectively a Phase III study being attempted without the prerequisite Phase I or II data, meaning it skips essential safety, dosing, and toxicity benchmarks, thereby exposing hundreds of participants to unnecessary risk from an unproven compound.